Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
Solomon A Graf,1–3 Jose M Garcia4,5 1Veterans Affairs Puget Sound Health Care System, 2Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, 3Clinical Research Division, Fred Hutchinson Cancer Research Center, 4Geriatric Research, Education and...
Main Authors: | Graf SA, Garcia JM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-08-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/anamorelin-hydrochloride-in-the-treatment-of-cancer-anorexia-cachexia--peer-reviewed-article-DDDT |
Similar Items
-
Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
by: Koichi Takayama, et al.
Published: (2023-02-01) -
Ameliorating effects of cystine and theanine in a cancer cachexia mouse model
by: Hibiki Kudamatsu, et al.
Published: (2023-07-01) -
Metabolism Study of Anamorelin, a GHSR1a Receptor Agonist Potentially Misused in Sport, with Human Hepatocytes and LC-HRMS/MS
by: Prince Sellase Gameli, et al.
Published: (2023-08-01) -
Pharmacological inhibition of IRAK4 kinase activity does not prevent cachexia in mice with pancreatic cancer
by: Shuxi Qiao, et al.
Published: (2023-07-01) -
A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome
by: Ivy O. Poon, et al.
Published: (2024-02-01)